Checkpoint Therapeutics (NASDAQ:CKPT) Given Buy Rating at HC Wainwright

HC Wainwright restated their buy rating on shares of Checkpoint Therapeutics (NASDAQ:CKPT) in a research note released on Thursday morning,Benzinga reports. They currently have a $20.00 target price on the stock.

Checkpoint Therapeutics Trading Down 8.5 %

CKPT stock traded down $0.32 on Thursday, hitting $3.46. The company had a trading volume of 656,303 shares, compared to its average volume of 522,220. Checkpoint Therapeutics has a 12-month low of $1.36 and a 12-month high of $3.97. The stock has a market cap of $155.77 million, a price-to-earnings ratio of -1.92 and a beta of 1.23. The stock’s 50-day simple moving average is $2.79 and its 200 day simple moving average is $2.33.

Checkpoint Therapeutics (NASDAQ:CKPT) last released its quarterly earnings results on Tuesday, November 12th. The company reported ($0.23) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.15) by ($0.08). Research analysts forecast that Checkpoint Therapeutics will post -0.81 earnings per share for the current year.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in CKPT. Vanguard Group Inc. increased its stake in shares of Checkpoint Therapeutics by 67.4% in the 1st quarter. Vanguard Group Inc. now owns 917,894 shares of the company’s stock worth $1,882,000 after purchasing an additional 369,586 shares in the last quarter. B. Riley Wealth Advisors Inc. grew its holdings in Checkpoint Therapeutics by 366.3% during the second quarter. B. Riley Wealth Advisors Inc. now owns 229,200 shares of the company’s stock valued at $493,000 after purchasing an additional 180,050 shares during the period. PVG Asset Management Corp purchased a new stake in Checkpoint Therapeutics in the second quarter worth about $295,000. Wealth Enhancement Advisory Services LLC increased its position in Checkpoint Therapeutics by 160.0% in the third quarter. Wealth Enhancement Advisory Services LLC now owns 130,000 shares of the company’s stock worth $291,000 after buying an additional 80,000 shares in the last quarter. Finally, Walleye Capital LLC bought a new position in shares of Checkpoint Therapeutics in the third quarter worth about $148,000. 22.00% of the stock is currently owned by institutional investors.

About Checkpoint Therapeutics

Checkpoint Therapeutics, Inc, a clinical-stage immunotherapy and targeted oncology company, focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers in the United States and internationally. The company's lead antibody product candidate is Cosibelimab, which is in Phase 1 clinical trial to treat patients with selected recurrent or metastatic cancers; and CK-302, a product candidate in preclinical trials for hematological malignancies and solid tumors.